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Abstract
Background: The role of naturally occurring regulatory T cells (Treg) in the control of the development of systemic lupus
erythematosus (SLE) has not been well defined. Therefore, we dissect the phenotypically heterogeneous CD4
+FoxP3
+ T cells
into subpopulations during the dynamic SLE development.
Methodlogy/Principal Findings: To evaluate the proliferative and suppressive capacities of different CD4
+ T cell subgroups
between active SLE patients and healthy donors, we employed CD45RA and CD25 as surface markers and
carboxyfluorescein diacetatesuccinimidyl ester (CFSE) dilution assay. In addition, multiplex cytokines expression in active
SLE patients was assessed using Luminex assay. Here, we showed a significant increase in the frequency of
CD45RA
+FoxP3
low naive Treg cells (nTreg cells) and CD45RA
2FoxP3
low (non-Treg) cells in patients with active SLE. In
active SLE patients, the increased proportions of CD45RA
+FoxP3
low nTreg cells were positively correlated with the disease
based on SLE disease activity index (SLEDAI) and the status of serum anti-dsDNA antibodies. We found that the surface
marker combination of CD25
+CD45RA
+ can be used to defined CD45RA
+FoxP3
low nTreg cells for functional assays, wherein
nTreg cells from active SLE patients demonstrated defective suppression function. A significant correlation was observed
between inflammatory cytokines, such as IL-6, IL-12 and TNFa, and the frequency of nTreg cells. Furthermore, the
CD45RA
+FoxP3
low nTreg cell subset increased when cultured with SLE serum compared to healthy donor serum, suggesting
that the elevated inflammatory cytokines of SLE serum may promote nTreg cell proliferation/expansion.
Conclusions/Significance: Our results indicate that impaired numbers of functional CD45RA
+FoxP3
low naive Treg cell and
CD45RA
2FoxP3
low non-suppressive T cell subsets in inflammatory conditions may contribute to SLE development. Therefore,
analysis of subsets of FoxP3
+ T cells, using a combination of FoxP3, CD25 and CD45RA, rather than whole FoxP3
+ T cells, will
help us to better understand the pathogenesis of SLE and may lead to the development of new therapeutic strategies.
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Introduction
Human regulatory T cells (Treg cells) play an important role in
T cell homeostasis and are critical regulators of immune tolerance
[1]. Quantitative and/or qualitative deficiencies in Treg cells
could lead to the development of autoimmune diseases [2,3,4].
Systemic lupus erythematosus (SLE) is a systemic autoimmune
disease that is characterized by the presence of autoantibodies and
immune complexes that target multiple organ systems. A
deficiency in Treg cells results in the development of lupus-like
characteristics, including glomerulonephritis and the development
of DNA-specific antibodies, which might indicate failure of Treg
cell-mediated suppression [5,6,7,8,9].
Many studies have assayed the number of Treg cells in the
peripheral blood of SLE patients [10]. However, the reports on Treg
cell numbers and function in SLE patients have been contradictory
[11]. The lack of Treg-specific markers presents a challenging
problem for the isolation and analysis of Treg cells. Importantly,
FoxP3
+ Treg cells may not be a functionally homogenous
population. FoxP3 is constitutively expressed by Treg cells and is
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34662also induced in activated T cells [12,13,14]. This may explain the
inconsistent results regarding the number of CD4
+FoxP3
+ cells
reported for SLE patients. More recently, two groups reported that
the percentage of CD4
+CD25
+FoxP3
+ Treg cells is normal, whereas
CD4
+CD25
2FoxP3
+ T cells are significantly and consistently
increased in patients with new onset SLE [15,16]. However, those
CD4
+FoxP3
+cellsinSLEpatientsareCD25
lowor CD25
2,an dt he ir
identity has not been characterized. Whether subpopulations of
FoxP3
+ T cells are functionally different or reliably delineated is not
known.Inaddition, howsuchsubsets differinproportionorfunction
in the development of SLE remains to be determined. To
characterize functionally heterogeneous CD4
+FoxP3
+ Tc e l l s ,w e
employed CD45RA as a delineating surface marker for
CD4
+FoxP3
+ cell subpopulations in SLE patients. It has been
reported that some FoxP3
+ cells are phenotypically naive
(CD45RA
+) in peripheral blood and exhibit a suppressive function,
whereas other FoxP3
+ cells phenotypically resemble memory T cells
(CD45RA
2)[4].Miyaraetal.haveshownthathumanFoxP3
+CD4
+
T cells can be separated into three functionally and phenotypically
unique subpopulations, based on the expression of FoxP3 and their
cell surface phenotype [17]. The three distinct subpopulations are as
follows: (1) CD45RA
+FoxP3
low naive Treg cells (nTreg cells), (2)
CD45RA
2FoxP3
high activatedTregcells(aTregcells),bothofwhich
are suppressive in vitro; and (3) non-suppressive cytokine-secreting
CD45RA
2FoxP3
low T cells (non-Treg cells). It has also been
documented that the relative proportions of FoxP3
+ Tc e l l
subpopulations show changes in dynamics in autoimmune diseases
and Treg cell differentiation [4]. For instance, previously conflicting
results may be interpreted as a change in circulating CD45RA
+
nTreg cells into CD45RA
2 aTreg. Furthermore, investigation of
CD45RA expression on FoxP3
+ cells might provide a consensus on
the functional status of Treg cells in the development of SLE.
The development of SLE is also related to cytokine dysregu-
lation. Cytokines assume a critical role in the differentiation,
maturation and activation of T cells during SLE pathogenesis. In
our previous study and in reports from other groups, proin-
flammatory cytokines, such as IL-1, IL-6, TNFa and cyclooxy-
genase-2 (COX-2), have been found to promote Treg prolifera-
tion/expansion, and to also support the proliferation of effector T
cells (Teffs) [18,19]. In addition, these cytokines have been shown
to make Teffs relatively resistant to suppression by Treg cells
[20,21]. Not previously described, however, is a cytokine that can
preferentially promote the activation of Teffs, while inhibiting
Treg cell expansion. Whether the elevated levels of proinflamma-
tory cytokines in SLE patients also contributes to the late
generation of Treg cells is still unknown.
Here we report the characterization of the CD4
+FoxP3
+ T cell
subpopulation in SLE development by using CD4, CD25 and
CD45RA as surface markers of expression, thereby avoiding
FoxP3
+ non-Treg cells. We also explore the correlation with
FoxP3, and determine its influence on Treg cell function,
especially in the more activated stage of SLE. Furthermore, our
data show that the high frequency of CD4
+CD45RA
+FoxP3
low
nTreg cells is associated with the production of proinflammatory
cytokines, including IL-6, IL-12 and TNFa, but not IL-17.
Results
Lack of correlation between FoxP3 and CD25 in CD4
+ T
cells of SLE patients
We compared the numbers of Treg cells in the peripheral blood
from SLE patients and healthy donors by analysing the expression
of FoxP3, a transcription factor critical to the development of Treg
cells. When detecting distinct subsets of FoxP3
+ T cells, based on
the expression of CD25, there were considerably higher numbers
of FoxP3
+ cells that were CD25 dull or negative present in active
SLE patients as compared to inactive SLE patients and healthy
controls (Fig. 1A). There was a significant increase in the
percentage of CD4
+FoxP3
+ cells in active SLE patients compared
with either inactive SLE patients or healthy donors (Fig. 1B, left).
In addition, the proportion of CD25
+FoxP3
+ cells was comparable
among healthy donors (3.960.4%), inactive (3.760.5%) and
active SLE (3.060.9%) (Fig. 1B, middle). In contrast, a significant
increase in the mean percentage of CD25-FoxP3
+ CD4
+ T cells
was observed in patients with active SLE (7.460.8%) when
compared with that of normal controls (3.260.4%, p,0.01), or
that of SLE patients with inactive disease (4.460.4%, p,0.05)
(Fig. 1B, right), suggesting that in active SLE patients the
CD4
+FoxP3
+ T cells are not correlated with the number of
CD4
+CD25
+ T cells. There was no significant difference in the
proportion of CD4
+CD25
2FoxP3
+ cells between healthy donors
and inactive SLE patients, although there was a trend toward an
increase in CD4
+CD25
2FoxP3
+ cells in the latter. The FoxP3
+
subset of CD4
+CD25
+ cells was comparable in these three groups,
suggesting that FoxP3 expression in CD4
+ T cells from active SLE
patients is dissociated from the CD4
+CD25
+ phenotype and, at
least to some extent, reflects the activation of CD4
+ T cells.
Increased CD45RA
+FoxP3
low and CD45RA
2FoxP3
low T cell
subsets in active SLE patients
Because of the different levels of FoxP3 expression with
CD45RA staining as shown in Fig. 1C, we could separate three
distinct CD4
+FoxP3
+ T subpopulations with a precise phenotype:
CD45RA
+FoxP3
low naive Treg cells (nTreg cells); CD45RA
2-
FoxP3
high activated Treg cells (aTreg cells); and CD45RA
2Fox-
P3
low (non-Treg cells). We observed a significant increase in
CD45RA
+FoxP3
low and CD45RA
2FoxP3
low subsets in CD4
+ T
cells in patients with active SLE (2.160.4%; 7.261.0% respec-
tively) compared with values found in healthy donors (1.360.2%;
4.660.6% respectively, p,0.05) or in patients with inactive SLE
(1.160.1%; 5.160.4% respectively, p,0.05) (Fig. 1D, subpopu-
lations Fr I and Fr III). However, there was no significant
difference in CD45RA-FoxP3
high cells between the groups. The
absolute numbers of this T cell subset was also supported for
increased the subpopulations Fr I and Fr III(Fig. 1D right). The
significant increase in CD45RA
+FoxP3
low T cells and CD45RA
2-
FoxP3
low T cells, and identification of the distinct subpopulations
of FoxP3
+ cells by CD45RA in patients with active SLE will
provide us with information on the functional status of
CD4
+FoxP3
+ T cells during SLE development.
Correlation of CD45RA subsets and CD25-defined Treg
cells
In patients with active and inactive SLE, T cells have been
reported to display an activated phenotype through various
markers for activated T cells [10]. To address whether different
expression levels of FoxP3 in patients with active SLE might be
related to their T cell activation phenotype, CD4
+FoxP3
+ T cells
were analyzed for their expression of CD45RA. As shown in Fig. 1,
significantly higher proportions of FoxP3
+ T cells were observed in
CD45RA
+FoxP3
low and CD45RA
2FoxP3
low subsets in patients
with active SLE. We focused on the correlation of these two
populations with CD25
2FoxP3
+ T cells. Comparative analyzes
were performed in patients with active SLE. As shown in Fig. 2A,
CD25 expression is different in CD45RA/FoxP3-defined T cell
subsets. The CD45RA
2FoxP3
high (Fr II) subset contains higher
percentage and intensity of CD25 positive cell. In contrast, the Fr I
Subpopulations of FoxP3+ T Cells in SLE
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e34662Figure 1. Phenotypic characterization of CD4
+FoxP3
+ T subset cells in patients with systemic lupus erythematosus (SLE). (A) PBMCs
were gated on CD4
+ T cells and analyzed for CD25 and FoxP3 expression by FCM. Data are representative of 5 independent experiments from healthy
donors, and patients with inactive and active SLE. (B) Percentages of CD4
+FoxP3
+ T cells, CD4
+CD25
2FoxP3
+ T cells and CD4
+CD25
+FoxP3
+ T cells
among CD4
+ T cells in healthy donors (n=15), inactive SLE (n=26) and active SLE patients (n=15). Data represent the mean 6 SEM. ns, means no
significant differences. (C) Five subsets of CD4
+ T cells are defined by the expression of CD45RA and FoxP3: CD45RA
+FoxP3
low cells (I);
CD45RA
2FoxP3
high cells (II); CD45RA
2FoxP3
low cells (III); CD45RA
2FoxP3
2 cells (IV); CD45RA
+FoxP3
2 (V) cells. Representative dot plots are shown for
a healthy donor and an active SLE patient. (D) The percentages and absolute numbers of different CD4
+ T cell fractions I, II, and III were analyzed in
healthy donors (n=15), inactive SLE (n=26) and active SLE patients (n=15). Data represent mean 6 SEM. ns, means no significant differences. *,
mean p,0.05.
doi:10.1371/journal.pone.0034662.g001
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34662Figure 2. The relationship between the CD45RA/FoxP3-definded subsets of T cells and CD25/FoxP3-defined Treg cells in SLE. (A)
The proportion of CD45RA
+ FoxP3
low (I), CD45RA
2FoxP3
high (II), CD45RA
2FoxP3
low cells (III), CD45RA
2FoxP3
2 cells (IV) and CD45RA
2FoxP3
2 cells (V)
were analyzed in relation to CD25 expression in active SLE patients. Mean Fluorescence Intensity (MFI) was indicated in different CD4
+ T cell
subpopulation. Data are representative of 5 independent experiments. (B) Expression of CD127 on CD25
high, CD25
mid, CD25
low subpopulation of
CD4
+FoxP3
+ T cell from patients with active SLE. Data are representative of 5 independent experiments. (C) Expression of CD127 on CD45RA
+FoxP3
low
(I), CD45RA
2FoxP3
high (II), CD45RA
2FoxP3
low cells (III) subpopulation of CD4
+FoxP3
+ T cell from patients with active SLE. Data are representative of 5
independent experiments. (D) The correlation between CD45RA
+/2FoxP3
+ and CD25
2FoxP3
+ Treg cells in SLE patients (n=31). The solid line shows
the regression curve. (E) The correlation between CD45RA
+/2FoxP3
+ and CD25
+FoxP3
+ Treg cells in SLE patients (n=31). The r value represents the
calculated regression coefficient. The p value indicates the correlation index between the groups.
doi:10.1371/journal.pone.0034662.g002
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34662and III subsets T cell express medium or low CD25. We gated
CD127
low/2 expression on CD4
+Foxp3
+ T cells, dependent on
CD25 or CD45RA, respectively. We found that all CD4
+Foxp3
+
T cells had a low expression level of CD127, and percentages of
CD127
low/2 in CD25
high and CD25
mid were higher than that in
CD25
low subpopulations of CD4
+Foxp3
+ T cells (Fig. 2B).
Furthermore, the expressions of CD127
low/2 on CD45RA/FoxP3
defined T cells subpopulation showed significant differences in
CD25high, CD25low, and CD25- subpopulations (Fig. 2C).
CD127
low/2 expressions were high in CD45RA
2FoxP3
high (II)
but low in CD45RA
+FoxP3
low (I) and CD45RA
2FoxP3
low (III)
subpopulations. This result suggested that CD127
low/2 was not a
perfect candidate surface marker for intracellular FoxP3 in
CD4+CD25- T cells in patients with SLE. We then analyzed this
correlation, and our results show that CD45RA
2FoxP3
low T cells
were significantly correlated to the CD25
2FoxP3
+ subset (Fig. 2D).
In addition, the proportions of CD45RA
+FoxP3
low T cells were
significantly correlated to the proportions of CD25
+FoxP3
+ T
cells, suggesting that the CD45RA
+FoxP3
low subset may be naive
Treg cells that have suppressive capability (Fig. 2E). In contrast,
there was no correlation between proportions of CD45RA
+Fox-
P3
low and CD25
2FoxP3
+ T cells. These findings further
strengthened our confidence that CD45RA may be used as a
marker to sort FoxP3
+ T cells in a CD4
+ T cell population.
Correlation of CD45RA subsets in SLE development
To determine whether the appearance of CD45RA subsets is
linked to clinical disease, we analyzed the correlation of CD45-
defined FoxP3
+ T cell subsets with SLE disease activity scores. The
CD45RA subset was also compared with status of anti-dsDNA
antibody in patients. As described above, significantly higher
proportions of CD45RA
+FoxP3
low nTreg cells and CD45RA
2-
FoxP3
low non-Treg cells were observed in PBMCs from patients
with active SLE as compared to healthy donors. The most
noteworthy finding is that a significant correlation was found for
populations of CD45RA
+FoxP3
low T cells with the SLEDAI score
(r=0.55, p,0.05) (Fig. 3A). We examined the presence of anti-
dsDNA using an ELISA test, then separated the patients into two
groups that were anti-dsDNA positive (5 cases) or anti-dsDNA
negative (10 cases). Regarding the subsets of Treg cells, the
percentage of CD45RA
+FoxP3
low regulatory T cells was signifi-
cantly higher in the anti-DNA positive group. This may be due to
an impairment of the main suppressive function in this subset of
rTregs, through an increase in the number of CD45RA
+FoxP3
low
regulatory T cells to overcome the control of the autoimmune
response(Fig. 3B).
Impairment of the suppressive function of the
CD45RA
+FoxP3
lowsubset in patients with active SLE
Because the CD4
+CD45RA
+ subset may resemble Treg or
activated T cells, according to the phenotypic analyzes described
above, we next sought to determine their suppressive capacity in
vitro. Due to the limitations of FoxP3 to separate human Treg cells
for functional studies we utilized the phenotypic strategy described
above. Specifically, for the characterization of functionally
heterogeneous populations of CD4
+FoxP3
+ T cells and to avoid
contamination with activated responder T cells, we performed a
combination of CD25, FoxP3 and CD45RA staining of CD4
+ T
cells in peripheral blood lymphocytes from normal donors and
patients with SLE. Similar to the FoxP3/CD45RA combination,
combined CD25/CD45RA surface expression can also be used to
Figure 3. The relationship between the CD45RAFoxP3 subset of T cells and clinical disease activity. Three subsets of FoxP3
+ T cells were
analyzed for clinical correlation. (A) A positive correlation between the proportion of CD45RA
+FoxP3
low (I) cells and clinical severity of the flare, scored
using the SLEDAI in active SLE patients (n=15). (B) A significant difference was observed for proportions of CD45RA
+FoxP3
low (I) cells in the status of
anti-dsDNA antibody in active SLE patients (n=15). Data represent the mean 6 SEM.
doi:10.1371/journal.pone.0034662.g003
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34662identify the five fractions (Fig. 4A, up). Our results showed that
FoxP3 expression is different in CD25/CD45RA-defined T cell
subsets (Fig. 4A, down), which FoxP3 mainly expressed in fraction
I, II, III subpopulations and fraction II Treg cell have higher MFI
of FoxP3 than fraction I and fraction II. To assess the suppressive
potency of each fraction, we first measured the extent of CFSE
dilution of labelled CD25
2CD45RA
+ T responder cells cocultured
with an equal number of a Treg fraction from healthy donors. Our
Figure 4. Functional characterization of the CD45RA/FoxP3-defined subset of T cells in SLE patients. (A) Five subsets of CD4
+ T cells
were defined by the expression of CD45RA and CD25: CD25
+CD45RA
+ cells (Fr. I); CD25
++CD45RA
2 cells (Fr. II); CD25
+CD45RA
2 cells (Fr. III);
CD25
2CD45RA
2 cells (Fr. IV); and CD25
2CD45RA
+ cells (Fr. V). Expression of FoxP3 and MFI of FoxP3 were analyzed in CD25 and CD45RA defined T
cell subsets. (B) CD4
+CD25
2CD45RA
+ responder T cells were labelled with CFSE, and cultured at a 1:1 ratio with unlabeled Fr.I, II, or III purified from
healthy donor (n=3). Cell proliferation was assessed by CFSE dilution. The percent suppression is shown. Statistical analysis of the suppression
percentage of T responder cells was performed by nonparametric Mann-Whitney U test. (C) Sorted CD4
+CD25
2CD45RA
+ responder T cells were co-
cultured with their autologous sorted Fr. I, II, or III, respectively, in order to assess the function of Fr. I/II/III cell suppression from healthy donors and
active SLE patients. Representative FCM data are shown. Statistical analysis of the suppression percentage of T responder cells was performed from 5
healthy donors and 5 patients with active SLE.
doi:10.1371/journal.pone.0034662.g004
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proliferation of responder cells, whereas fraction III failed to
inhibit the responder T cell proliferation. To investigate the
function of increased nTreg cells in SLE patients, we measured
and compared the function of CD25
+CD45RA
+ nTreg cells from
healthy donor and active SLE patients (Fig. 4B). There were no
significant differences in the suppressive activity of fraction II and
III cells between HD and active SLE patients (Fig. 4C). However,
CD45RA
+FoxP3
low T cells (Fr. I) from patients with active SLE
exhibited significantly less suppressive activity (17.367.0%) than
fraction I cells from healthy donors (41.266.5%, p,0.05) (Fig. 4C).
The suppressive rate of CD45RA
+FoxP3
low T cells from patients
with inactive SLE revealed a less striking, but significant decrease
in the percent inhibition of Tresp cell proliferation, as compared
with that of nTreg cells from healthy donors (data not show).
Increase in the CD45RA
+FoxP3
low T cell subset through
proinflammatory cytokines, but not IL-17
SLE is characterized by systemic inflammation. Therefore, the
induction of excessive levels of proinflammatory cytokines might,
in some way, promote or convert Treg cells. Through cytokine
analysis, serum levels of IL-6, IL-8, IL-10, IL-12, IFNa and TNFa
were significantly higher in active SLE patients than in healthy
donors (Fig. 5A). As illustrated in Table 1, the frequencies of
circulating CD45RA
+FoxP3
low (I) T cell subsets were significantly
and positively correlated with the levels of serum IL-1ß, IL-6, IL-
12, TNFa and IL-2 compared to other cytokines in SLE patients,
such as IFNa and IL-17. We found an increase in the
CD45RA
+FoxP3
low T cell subset in culture with SLE serum
(1.960.1%) compared to healthy donor serum (1.260.1%,
p,0.05), (Fig. 5B and C), which suggests that SLE serum contains
proinflammatory cytokines that can induce or promote expansion
of the CD45RA
+FoxP3
low nTreg cells. Furthermore, we can block
raising CD45RA
+FoxP3
low T cells by using TNFa
antibody(Fig. 5D). Which indicated that some specific cytokine
contributed Treg cell development in SLE.
Discussion
The observations on the number and function of Treg cells in
patients with SLE have, in many respects, been contradictory
[22,23,24]. This may be due to the presence of contaminating
active CD4
+ non-Treg cells, which can transiently express FoxP3,
resulting in a constant threat to Treg cell purity. However, there is
currently a lack of defined markers that can identify Treg
phenotypes that can replace the intracellular FoxP3 marker for
use in subsequent functional studies of Treg cells. Here, we report
increases in CD4
+CD45RA
+FoxP3
+ and CD4
+CD45RA
2Fox-
P3
low cells in active SLE patients. The increased
CD4
+CD25
2FoxP3
+ T cells in SLE patients may have been
derived from the CD4
+CD45RA
2FoxP3
low subset, which is a non-
regulatory T cell population without suppressive function. Further
studies of their suppressive function in vitro revealed that
CD45RA
+FoxP3
low T cells in active SLE failed to suppress
responder cell proliferation. Furthermore, CD45RA
+FoxP3
low
subsets were increased in active SLE through the release of
circulating cytokines, including IL-6, IL-12 and TNFa. Together,
these results suggest that Treg cells identified by CD45RA along
with CD25 and FoxP3 may indicate the disease activity in
peripheral blood of human SLE patients.
In the current study, we found an increased population of
CD45RA
+FoxP3
low T cells in active SLE patients. However, there
was no significant difference in the population of CD45RA
2Fox-
P3
high T cells between patients with active SLE and healthy
donors. Although CD45RA
2FoxP3
low T cells can possibly be
converted into CD45RA
2FoxP3
high T cells, which are terminally
differentiated and rapidly undergo apoptosis [25], the increased
frequency of CD45RA
+FoxP3
low is associated with defective
suppressive function in vitro, as well as the development of
DNA-specific antibodies in patients with active SLE. The
abnormal suppressive function of Treg cells in SLE patients may
be due to the resistance of SLE-associated effector T cells toward
Treg-mediated suppression, or the indirect blockade of Treg cell
effectiveness by antigen-presenting cells [26,27] This scenario
provides a rational explanation for the increase in peripheral blood
CD45RA
+FoxP3
low T cells, which correlated with the quantity of
CD4
+CD25
+FoxP3
+ Treg in active lupus, and may indicate a
positive feedback response to the resistant/blockade effect on Treg
cell suppression. This leads to the following question: Where do
the increased circulating CD4
+CD25
+FoxP3
+ Treg cells originate?
Most of the CD4
+CD25
+FoxP3
+ T cells in the peripheral blood
from patients with SLE have undergone autoantigen stimulation
and thus are derived from the memory CD4
+ T cell compartment.
To limit interference by CD45RA
+Foxp3T cell number with age,
we selected age-matched patients and healthy controls. Patients
and controls aged about 30–35 years old were enrolled in this
study. Although rTreg cells were decreased in aged donors, which
has been reported by Miyara et al [17], we observed a high
proportion of rTreg among CD4
+ T cells in active SLE patients
compare to age-matched healthy controls. There may be many
activated T cells in SLE patients or younger donors. Most of the
Foxp3
hi aTregs may be derived from activated and proliferating
rTreg cells, and a small fraction of aTreg cells derived from
Foxp3
2CD4
+ non-Treg cells in vivo. No significant increase in
aTreg cells was observed in our SLE patients, but we did find a
significant increase in rTreg and Foxp3
2CD4
+ non-Treg cells in
the patients with active SLE, which was consistent with the recent
report by Miyara et al [17]. Thus, the lower suppressive capacity
seen in coculture assays of CD45RA
+FoxP3
lowT cells from
patients with active SLE could be attributed either to an impaired
suppressor function of the Fr.I nTreg cells or to a resistance of
Tresp cells to Treg cell-mediated suppression. Moreover, despite
impaired nTreg cells suppressive function, the function of Tresp
cells resistance to Treg cells is not entirely clear. One further
consideration is that CD25
+CD45RA
2 T cells are not equivalent
in number to CD45RA
2FoxP3
low non-Treg cells in patients with
SLE because of the increase in CD4
+CD25
2FoxP3
+ T cells. With
regard to Tresp cells becoming relatively resistant to suppression
by Treg cells through the expression of specific cytokines, our in
vitro suppressive function assay using isolated Treg and Tresp cells
suggest that this is not the case. Nonetheless, the presence of
proinflammatory cytokines in vivo or in vitro may lead to
abrogated Treg cell suppressor function. In humans, it has been
suggested that memory CD4
+ T cells may be the peripheral origin
of adaptive CD4
+CD25
+FoxP3
+ cells, also called inducible Treg
cells [28,29]. Our current data provide evidence suggesting that
the variation in CD4
+CD25
+CD45RA
+ T cell frequency may
result from a defect in function or quality of these cells in active
SLE.
More recently, several groups have reported that there is a
considerable number of CD4
+CD25
2FoxP3
+ T cells present in
the peripheral blood of patients with SLE [11]. Therefore
speculations on increased or decreased proportions of Treg cells,
based on phenotypic analysis in patients with SLE, must be made
with caution, as increased proportions of activated T cells can be
observed under conditions of chronic inflammatory diseases [30]
and might contaminate assays relying of gated populations of Treg
cells. This prompted us to ask whether CD4
+CD25
2FoxP3
+ T
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performed detailed comparative phenotypic analyzes of
CD4
+CD25
+FoxP3
+ and CD4
+CD25
2FoxP3
+ from SLE patients
and healthy controls, and used a combination of CD45RA surface
markers to substitute for FoxP3, which allowed us to isolate these
cells for functional studies. Using the CD45RA marker, we
identified that the population of CD4
+CD25
2FoxP3
+ most likely
contained the CD45RA
+FoxP3
low and CD45RA
2FoxP3
low sub-
sets. The CD45RA
+FoxP3
high population was not significantly
different between HD and active SLE, although it was positively
correlated to the CD25
+FoxP3
+ subsets, suggesting that
CD25
+FoxP3
+ may be not an exclusive marker of Treg cells in
SLE, as it may be expressed in active T cells. The CD45RA
2-
FoxP3
low T cell population was not associated with suppressive
Figure 5. Proinflammatory cytokines contribute to CD45RA
+FoxP3
+ T cell development in SLE. (A) A series of cytokines were measured
by high sensitivity multiplex assay from the sera of healthy donors (n=15) and active SLE patients (n=15). *p,0.05 compared to healthy sera. (B)
Healthy isolated PBMCs were stimulated with the sera (1:5 dilutions) from autologous healthy donors or active SLE patients, cultured for 3 days and
analyzed for CD45RA and FoxP3 expression by FCM before and after culture. Representative FCM data was shown. (C) Statistical analysis of the
percentage of each FoxP3
+ subset among CD4
+ T cells was performed before and after culture as defined in (B) from 5 healthy donors and 5 active
SLE patients. *, p,0.05 compared to unstimulated control. (D) Healthy isolated PBMCs were stimulated by the sera (1:5 dilutions) from active SLE
patients with control IgG (10 mg/ml), anti-TNFa (10 mg/ml), anti-IL6 (10 mg/ml), anti-IL12 (10 mg/ml) respectively, cultured for 3 days and analyzed for
CD45RA and FoxP3 expression by FCM. Representative FCM data was shown. (E) Statistical analysis of the percentage of each FoxP3
+ subset among
CD4
+ T cells was performed as defined in (D) from 5 active SLE patients. *, p,0.05 compared to control IgG.
doi:10.1371/journal.pone.0034662.g005
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healthy donors. Based on our data, we conclude that
CD4
+CD25
2FoxP3
+ T cells in SLE patients share several
properties with conventional Treg, but are otherwise distinct in
certain functional qualities.
As SLE is characterized by systemic inflammation, the
induction of excessive levels of proinflammatory cytokines [31]
may ‘‘prime’’ the Tresp cells to develop resistance to Treg cell-
mediated suppression, as seen in our suppressor assays. The
inflammatory cytokines of the local environment might be
responsible for this effect. These cytokines could be produced by
the Tresp cells themselves, in an autocrine manner, or be
produced by other cell types within the inflammatory environ-
ment. The abrogation of Treg cell function in suppressor assays in
the presence of proinflammatory cytokines such as IL-1 [21],
TNFa [32], IL-6 [33], and IL-12 [34] in mice or humans, and the
high levels of Treg cells in human SLE, have led us to initiate
studies on the role of these cytokines. Our results show that
proinflammatory cytokine production is significantly increased in
the serum of patients with active SLE, including IL-6, TNFa and
IL-12, and these cytokines were positively correlated with
CD45RA
+FoxP3
low T cells. Furthermore, we were able to induce
CD45RA
+FoxP3
low T cells from naı ¨ve T cell by using those sera
that contained proinflammatory cytokines from SLE patients. In
our experiments, we can block the increase in CD45RA
+FoxP3
low
T cells by using TNFa antibody, which indicates that there is a
specific cytokine contribution to Treg cell development in SLE.
Although characteristics of the SLE marker IFNa were elevated in
SLE patients [35], this was not associated with nTreg cells. The
contribution of type I interferon to the development of SLE has
been a long-standing interest of Shen and other groups. More
recent data from Shen and others have addressed elevated levels of
IFNa by antigen-presenting cells (APCs) from patients with active
SLE, which inhibited Treg cell suppressive function [27]. We also
found nTreg cells from patients with active SLE with a defective
suppression function. Whether the defect in those subsets of Treg
cells is mediated by IFN needs to be studied further. We also
report that the increased CD45RA
+FoxP3
low subset in active SLE
was linked to a lack or abrogation of suppressive function, which
further supports the finding that abnormally increased nTreg cells
in active SLE are unable to suppress the systemic immune
response and proinflammatory cytokine production. Future studies
will need to evaluate the mechanisms by which proinflammatory
cytokines generate Tresp cell resistance. It is already known that
hyperactivation of certain intracellular signaling pathways, such as
the phosphatidylinositol 3-kinase/Akt pathway, can contribute to
this process in different genetically engineered mouse models that
are prone to developing autoimmune diseases [36].
In summary, we have identified an increase in the subset of
CD45RA
+FoxP3
low T cells that contributes to SLE progression
with aberrant inflammatory status. We propose that the
combination of CD25 and CD45RA is therefore the best set of
markers for identifying human FoxP3
+ Treg cells as nTreg and
aTreg cells. This distinction is highly informative in assessing the
dynamics of Treg cell differentiation under physiological and
disease conditions. Impaired functions and numbers of CD45RA
+-
FoxP3
low nTreg cells and CD45RA
2FoxP3
low non-Treg cell
subsets in inflammatory conditions may contribute to SLE
development. By analyzing a subset of FoxP3
+ T cells, rather
than whole FoxP3
+ T cell population, may help us to better
understand the pathogenesis of SLE and support the development
of novel therapeutic strategies.
Materials and Methods
Patients and controls
Forty-one SLE patients (mean 6 SD age 32.767.4 years) who
met the revised SLE criteria of the American College of
Rheumatology [37,38] and fifteen age- and sex-matched healthy
donors (HD) (mean 6 SD age 30.465.9 years) were enrolled in
this study. In our study, we only included the patients who were
not receiving drugs at the time of the study. Prior to participation,
written informed consent was obtained from all subjects. All
studies were performed in accordance with the Declaration of
Helsinki. The study was approved by the Research Ethics Board of
Xinhua Hospital, Shanghai Jiao Tong University School of
Medicine. All patients were diagnosed as having SLE according
to the revised SLE Disease Activity Index (SLEDAI), and a score
$5 defined active diseases. According to their disease activity,
patients were divided into two groups. One group comprised 15
patients with active SLE (median SLEDAI score 10 [range 6–15]),
and a second group comprised 26 patients with inactive SLE
(median SLEDAI score 2 [range 0–4]). Healthy donors had no
acute or chronic inflammatory or infectious disease, ongoing
thrombosis, or neoplasia. The following were measured in the SLE
patients in the clinical immunology laboratory of the Xinhua
Hospital: differential white cell count; anti-double-stranded DNA
(dsDNA); immunoglobulin G (IgG); and the levels of plasma
Table 1. The correlation of CD4
+Foxp3
+ T cell subsets with serum cytokines in patients with active SLE.
Cytokines CD45RA
+FoxP3
low T cell (I) CD45RA
2FoxP3
high T cell (II) CD45RA
2FoxP3
low T cell (III)
rp rp rp
IL-12 0.91 ,0.01* 0.50 0.10 0.22 0.49
IL-6 0.69 0.02* 0.16 0.62 20.39 0.21
IL-1b 0.77 0.01* 20.23 0.47 20.22 0.49
TNF-a 0.69 0.02* 0.42 0.17 0.01 0.98
IL-2 0.84 0.01* 0.01 0.98 20.29 0.37
IFN-c 20.20 0.51 20.23 0.46 0.79 0.01*
IL-17 20.22 0.50 0.03 0.94 20.61 0.04*
IFN-a 20.20 0.51 20.23 0.46 20.50 0.10
IL-10 0.28 0.38 0.19 0.56 20.01 0.98
*p,0.05, Spearman’s rank correlation tests.
doi:10.1371/journal.pone.0034662.t001
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performed in parallel with the analysis of CD4
+FoxP3
+ T cell
subpopulations.
Phenotypic analysis
Peripheral blood mononuclear cells (PBMCs) were freshly
isolated by Ficoll-Hypaque density gradient centrifugation.
PBMCs were re-suspended in PBS supplemented with 2% bovine
serum albumin at a concentration of 1610
6 cells/ml. Fluoro-
chrome-labeled mouse anti-human monoclonal antibodies target-
ed against CD45RA-PE, CD3-ECD, CD25-PC5 and CD4-PC7
were purchased from Beckman Coulter. FoxP3-FITC and IgG2a-
FITC (eBioscience) were used, together with appropriate isotype
controls, to permit the identification of positive and negative cell
populations. Intracellular FoxP3 staining was performed according
to the manufacturer’s instructions. Multiple-color flow cytometry
(FCM) analysis was performed using a BD FACS Aria flow
cytometer (BD). For cell sorting, peripheral blood was collected
from either healthy donors or SLE patients, and PBMCs were
isolated and stained with the relevant fluorochrome-labeled
monoclonal antibodies. The FACS Aria Flow cytometer was
adjusted with Accudrop (BD) for optimum sorting conditions. The
purity of sorted cells was verified after sorting and was .95%.
Functional assays
PBMCs from SLE patients or healthy donors were isolated and
sorted into CD4
+CD25
+CD45RA
+, CD4
+CD25
highCD45RA
2,
CD4
+CD25
+CD45RA
2, and CD4
+CD25
2CD45RA
+ subpopu-
lations by FCM. Purity of each sorted population was consistently
.95%. The CD25
high gate was adjusted to contain CD4
+ T cells
that express CD25 more brightly than CD4
+CD25
+ cells. RPMI
1640 medium supplemented with 10% fetal bovine serum,
100 IU/ml penicillin, and 100 mg/ml streptomycin (Sigma) was
used for T cell cultures. For the carboxyfluorescein diacetate
succinimidyl ester (CFSE) dilution assay, CD4
+CD25
2CD45RA
+
responder T (Tresp) cells were labeled with 1 mmol/ml CFSE
(Invitrogen) for 8 min at 37uC. 1610
4 CD4
+CD25
2CD45RA
+ T
cells were co-cultured in the presence or absence of sorted CD4
+
subsets cells for assessing their suppressive capacity at 1:1.
Subsequently, mixed T cell cultures were stimulated with anti-
CD3/CD28 coated beads (Dynal Biotech) in 96-well plates for 4
days. Proliferation of CFSE-labeled cells was analyzed by flow
cytometry either immediately or after 4 days.
Serum stimulation assay
Healthy PBMCs were stimulated with serum (1:5 dilutions) from
healthy donors or active SLE patients, cultured for 3 days and
analyzed by FCM before and after culture, as described above.
Cytokine assays
Sera derived from patients with SLE and healthy donors were
collected and frozen at 270uC until used. Serum cytokine levels
were measured using an immunobead-based 20-plex assay
(Luminex) and included the following cytokines: IL-1a, IL-1b,
IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p40),
IL-12(p70), IL-13, IL-15, IL-17, IFNc, IFNa, TNFa and TNFb.
Panels of capture antibody-coated beads and labeled detection
antibodies were purchased from Millipore, which were pretested
and qualified by the manufacturer to ensure the absence of cross-
reactivity. The assay sensitivity varied from 5 to 15 pg/ml
depending on the analysis. The assays were performed using the
Luminex 200 System (Luminex).
Statistical analysis
Analysis of the data was performed using GraphPad Prism
version 5.0 for Windows (GraphPad Software, San Diego, CA,
USA). Values are expressed as mean 6 SEM unless otherwise
indicated. The Kolmogorov-Smirnov test was used to evaluate the
distribution of each parameter. For data with normal distribution
and homogeneity of variance, an independent-sample t test was
used to compare differences between two groups, and a one-way
ANOVA with Tukey’s post-hoc test was performed if there were
three or more means. The Mann-Whitney test was used to
compare data with a non-normal distribution. Correlations were
assessed by Spearman’s rank correlation coefficients and signifi-
cance was determined after a Bonferroni correction. A value of
p,0.05 was considered significant in all statistical tests.
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